Coenzyme Q$_{10}$ and congestive heart failure: an evolving evidence base

Christopher M. Florkowski, Sarah L. Molyneux, Joanna M. Young

Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand

**THE Q-SYMBIO STUDY AND ITS IMPLICATIONS**

The recently published Q-SYMBIO clinical trial has provided support that coenzyme Q$_{10}$ (CoQ$_{10}$) supplementation should be considered as a part of the maintenance therapy of patients with chronic heart failure (CHF) [1]. The Q-SYMBIO study concluded that long-term CoQ$_{10}$ treatment of patients with CHF is safe, improves symptoms, and reduces major adverse cardiovascular (CV) events [1].

This was a randomised, controlled, double-blind intervention trial (RCT), conducted in many centres in nine countries including Poland.

Q-SYMBIO was initiated with CoQ$_{10}$ supplementation in CHF patients and focused on symptoms, biomarker status (BNP) and long-term outcomes.

A total of 420 patients with moderate to severe CHF were randomly assigned in a two-year prospective trial to either CoQ$_{10}$ 100 mg three times daily or a placebo, in addition to standard therapy. There were no changes in primary end-points at 16 weeks. These included changes in New York Heart Association (NYHA) functional classification, six-min walk test, and levels of N-terminal pro-B type natriuretic peptide (NT-proBNP).

The primary long-term end-point (composite major adverse CV events as determined by a time-to-first-event analysis), was reached by 15% of the patients in the CoQ$_{10}$ group vs. 26% in the placebo group (hazard ratio [HR] 0.50; 95% confidence interval [CI] 0.32–0.80; p = 0.003) by intention-to-treat analysis (Fig. 1). This included secondary end-points, which were significantly lower in the CoQ$_{10}$ group compared to the placebo group: CV mortality (9% vs. 16%; p = 0.026), all-cause mortality (10% vs. 18%; p = 0.018), and incidence of hospital stays for heart failure (HF) (p = 0.033). In addition, a significant improvement of NYHA class was found in the CoQ$_{10}$ group after two years (p = 0.028).

Q-SYMBIO is the first RCT with adequate size, dosage of CoQ$_{10}$, and duration of follow-up to evaluate the efficacy of CoQ$_{10}$ on morbidity and most importantly, major clinical end-points such as mortality in CHF.

The findings have implications for clinical practice, by providing a more robust evidence base for CoQ$_{10}$ intervention in CHF patients. In addition, it has a good safety profile and is readily available over the counter without prescription.

The present review examines the background as to why the Q-SYMBIO study came about. Starting with the role of CoQ$_{10}$ in biological systems, it covers what previous studies have discovered about CoQ$_{10}$ and cardiac function. This includes observational studies, intervention studies prior to Q-SYMBIO, meta-analyses [2–4] and a Cochrane review [5]. Statin drugs, used to lower cholesterol as part of CV prevention strategies, are also known to lower CoQ$_{10}$ through their action on the mevalonate pathway [6]. The present review discusses the findings of studies with statin intervention in CHF and their implications. It also provides a commentary of Q-SYMBIO with caveats and recommendations for future studies.
THE ROLE OF COENZYME Q<sub>10</sub> IN BIOLOGICAL SYSTEMS

CoQ<sub>10</sub> (Fig. 2), a benzoquinone with an isoprenoid side chain, was first isolated from beef heart mitochondria by Frederick Crane of Wisconsin, USA, in 1957 [7]. CoQ<sub>10</sub> is present in the body in both a reduced (ubiquinol, CoQ<sub>10</sub>H<sub>2</sub>) and an oxidised (ubiquinone, CoQ<sub>10</sub>) form. CoQ<sub>10</sub> is lipophilic and transported in lipoprotein particles in the circulation. It is not surprising therefore that plasma CoQ<sub>10</sub> correlates with plasma cholesterol and low density lipoprotein (LDL)-cholesterol [8–15]. CoQ<sub>10</sub> is synthesised endogenously, and is also obtained from the diet, with meat products being the largest source in the normal diet [16].

CoQ<sub>10</sub> is an essential cofactor in mitochondrial oxidative phosphorylation, and is vitally important for adenosine triphosphate (ATP) production (Fig. 3). In this role, CoQ<sub>10</sub> acts as a mobile electron carrier, transferring electrons from complex 1 (NADH coenzyme Q reductase) to complex 3 (cytochrome bc<sub>1</sub> complex), or from complex 2 (succinate dehydrogenase) to complex 3. The reduced form of CoQ<sub>10</sub> can act as an antioxidant directly protecting biological membranes against oxidation [17] as well as by inhibiting the peroxidation of lipoprotein lipids in the circulation [18]. Indeed, supplementation with exogenous CoQ<sub>10</sub> has been shown to lead to an increase in the CoQ<sub>10</sub>H<sub>2</sub> content of LDL, and a decrease of their peroxidisability [19]. As an antioxidant, CoQ<sub>10</sub>H<sub>2</sub> may also have a role in recycling alpha-tocopherol, which may also have favourable implications for the pathogenesis of vascular disease [20].

COENZYME Q<sub>10</sub> AND CARDIAC FUNCTION

Given the vital importance of CoQ<sub>10</sub> in mitochondrial electron transport and ATP synthesis, it is not surprising that the myocardium has the highest concentration of CoQ<sub>10</sub> compared to other tissues [16] and its depletion has been postulated to lead to ‘energy starvation’ of the myocardium and have a pathogenic role in the aetiology of CHF. Indeed, myocardial depletion of CoQ<sub>10</sub> has been demonstrated in HF and the severity of the deficiency has been found to correlate with the severity of symptoms, with patients in NYHA class IV having significantly lower CoQ<sub>10</sub> in endo-myocardial biopsy samples than those in NYHA class I [21].

There are also some findings that suggest that oxidative stress is increased in patients with CHF, is inversely correlated with left ventricular ejection fraction (LVEF) [22], and may predict clinical outcomes [22]. Coenzyme Q<sub>10</sub> may also have a role in stabilising myocardial calcium-dependent ion channels and in preventing the consumption of metabolites essential for ATP synthesis [23].
COENZYME Q₁₀ AND HEART FAILURE

An interesting observation is that total cholesterol is related to survival in CHF [24, 25]. In the study of Rauchhaus et al. [24], serum total cholesterol was independently associated with total mortality in a CHF cohort, with increasing serum cholesterol predicting survival (HR 0.64, 95% CI 0.48–0.86), independent of the aetiology of CHF, age, LVEF and exercise capacity [24]. Although this seems somewhat counter-intuitive, postulated mechanisms for this association were that cholesterol may be limiting lipo-polysaccharide-induced production of cytokines, and that high cholesterol may provide a greater ‘metabolic reserve’ to deal with the CHF syndrome. The authors did not, however, make reference to CoQ₁₀, which is known to correlate with plasma total and LDL-cholesterol concentration [8–15] and which could be postulated to explain the worse outcomes seen in CHF patients with low cholesterol. Cardiac cachexia (lean tissue wasting associated with HF) was not considered to be a contributory mechanism in this group of patients, given that lipid levels were no different between patients with and without cachexia and that survival was independent of the presence of cachexia [24].

In a recent observational study, our group showed that CoQ₁₀ level, but not statin therapy (known to lower CoQ₁₀ in HF [6]), was an independent predictor of total mortality in a cohort of 236 subjects with HF [26]. We were unable to confirm that cholesterol was associated with survival in this cohort [26], although our patients were older and were followed for longer than the cohort of Rauchhaus et al. [24].

The important role played by CoQ₁₀ in myocardial bio-energetics and cardiac function set the scene for numerous intervention studies and led to the conception of the Q-SYMBIO study [1, 27].

INTERVENTION STUDIES WITH COENZYME Q₁₀ IN HEART FAILURE

Over the past few decades, several uncontrolled observational studies have been reported in the CHF population. They measured symptoms, ejection fraction, left ventricular size, and quality of life measurements before and after treatment with CoQ₁₀. Although they show dramatic improvements, severe study design flaws have limited their applicability [28–35].

There are, however, several small, randomised, blinded trials comparing CoQ₁₀ with placebo dating back many decades. Some studies have shown that supplementation of CoQ₁₀ over a relatively short time can improve systolic function and reduce ventricular size, whereas others showed no advantage over placebo. It may be contended that these neutral trials lack adequate power to detect an advantage or, conversely, that positive trials may give an exaggerated effect size because of small sample sizes. It is also possible that certain patients respond to CoQ₁₀ supplementation and others do not, depending on the severity or aetiology of CHF. Results of these smaller trials have subsequently been pooled, in an attempt to increase power and provide insight into its true effectiveness.

Meta-analyses of CoQ₁₀ supplementation in CHF have been undertaken [3, 36, 37]. Soja and Mortensen [36] reviewed eight double-blind placebo-controlled studies [38–45] and reported significant improvements in stroke volume, ejection fraction, cardiac output, cardiac index, and end-diastolic volume index, as a consequence of CoQ₁₀ supplementation.

In another meta-analysis, Sander et al. [3] reviewed 12 studies, ten that evaluated ejection fraction [38, 40–42, 45–50] and two that evaluated cardiac output [44, 46] with CoQ₁₀ doses ranging from 60 to 200 mg/day and treatment...
increase. This therefore suggests that CoQ$_{10}$ therapy may be best targeted at patients who are intolerant of ACEI.

Unfortunately, beta-blockers were only used in one trial evaluated in this analysis [50]; therefore, subgroup analysis could not be performed to determine if concomitant beta-blocker or, for that matter, angiotensin II receptor blocker, or aldosterone-receptor antagonist therapy, would also negate the benefits of CoQ$_{10}$.

Given that patients with more severe CHF (NYHA classes III and IV) have lower plasma and myocardial levels of CoQ$_{10}$ than those with less severe HF (NYHA classes I and II), it was considered that those with the most severe HF (NYHA class IV) would benefit the most from CoQ$_{10}$, although this was periods ranging from one to six months (Table 1). Overall, a 3.7% (95% CI 1.59–5.77) net improvement in the ejection fraction was found, and cardiac output was increased on average of 0.28 L/min (95% CI 0.03–0.53) [3]. Although cardiac index and stroke volume were not significantly affected by themselves, only a few studies with these parameters were included in these analyses and it is possible that the analysis was underpowered.

### Table 1. Trials evaluating coenzyme Q$_{10}$ in heart failure in meta-analysis of Sander et al. [3]

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose used</th>
<th>Treatment duration</th>
<th>Aetiology of chronic HF</th>
<th>NYHA class</th>
<th>Other HF medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hofman-Bang, 1995; (n = 69) [45]</td>
<td>61 (10)</td>
<td>100 mg QD</td>
<td>3 months (no washout)</td>
<td>Ischaemic and non-ischaemic (idiopathic, hypertensive, valvular, other)</td>
<td>II–IV (76% class II)</td>
</tr>
<tr>
<td>Langsjoen, 1985; (n = 19) [47]</td>
<td>63</td>
<td>33.3 mg TID</td>
<td>3 months (no washout)</td>
<td>Idiopathic</td>
<td>III–IV</td>
</tr>
<tr>
<td>Morisco, 1994; (n = 6) [40]</td>
<td>29 (6.7)</td>
<td>50 mg TID</td>
<td>1 month (no washout)</td>
<td>4 CAD and 2 idiopathic</td>
<td>II–IV</td>
</tr>
<tr>
<td>Poggesi, 1991; (n = 18) [42]</td>
<td>67 (2.3)</td>
<td>50 mg BID</td>
<td>2 months (no washout)</td>
<td>13 idiopathic, 7 ischaemic</td>
<td>II–III</td>
</tr>
<tr>
<td>Serra, 1991; (n = 20) [44]</td>
<td>59 (6.6)</td>
<td>60 mg QD</td>
<td>1 month (no washout)</td>
<td>13 CAD, 7 hypertensive</td>
<td>II–III</td>
</tr>
<tr>
<td>Watson, 1999; (n = 27) [48]</td>
<td>55 (11)</td>
<td>33 mg TID</td>
<td>3 months (no washout)</td>
<td>77% idiopathic, 23% ischaemic</td>
<td>Mean 41 months duration, EF &lt; 35%</td>
</tr>
<tr>
<td>Parallel trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keogh, 2003; (n = 35) [49]</td>
<td>62 (8)</td>
<td>50 mg TID</td>
<td>3 months (no washout)</td>
<td>Ischaemic, valvular, idiopathic</td>
<td>II–III; EF &lt; 40%</td>
</tr>
<tr>
<td>Khatta, 2000; (n = 46) [50]</td>
<td>64</td>
<td>200 mg/day</td>
<td>6 months</td>
<td>59% ischaemic</td>
<td>III–IV (91% class III); EF &lt; 40%</td>
</tr>
<tr>
<td>Munkholm, 1995; (n = 22) [46]</td>
<td>57</td>
<td>100 mg BD</td>
<td>3 months</td>
<td>Ischaemic or dilated</td>
<td>II–III; EF &lt; 45%</td>
</tr>
<tr>
<td>Judy, 1986; (n = 10) [38]</td>
<td>66</td>
<td>100 mg/day</td>
<td>6 months</td>
<td>Various aetiologies</td>
<td>IV</td>
</tr>
<tr>
<td>Permanetter, 1992; (n = 25) [41]</td>
<td>52</td>
<td>100 mg/day</td>
<td>3 months</td>
<td>Idiopathic</td>
<td>I–III (60% class III)</td>
</tr>
</tbody>
</table>

ACEI — angiotensin-converting enzyme inhibitor; BB — beta-blockers; BD — twice daily; CAD — coronary artery disease; EF — ejection fraction; HF — heart failure; NYHA — New York Heart Association; QD — once daily; TID — three times daily
WHAT ARE THE IMPLICATIONS FOR STATIN THERAPY?

This also brings into perspective the role of statins and whether they may confer benefit or not in patients with CHF, given the likely underlying ischaemic aetiology in many patients [51]. Although they may be expected to confer benefit through cholesterol reduction, they also lower CoQ$_{10}$ [6], given that they work through the common mevalonate pathway (Fig. 4). However, the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) investigators failed to show a reduction in major vascular events in older patients with systolic HF [52].

Similarly, in the GISSI-HF study (which included CHF patients with both ischaemic and non-ischaemic aetiologies), there was also no reduction in vascular adverse outcomes with rosuvastatin therapy [53]. A plausible explanation for this may be the reduction in CoQ$_{10}$, as our group has shown to occur in patients with non-ischaemic HF [54]. We showed that 40 mg atorvastatin led to a 33% reduction in CoQ$_{10}$ levels in non-ischaemic HF subjects, though this did not compromise improvements in endothelial function [54]. There was also a significant association ($r = -0.585; p = 0.011$) between CoQ$_{10}$ reductions and improvement in endothelial function with forearm plethysmography, suggesting that the improvement in endothelial function with atorvastatin therapy is mediated through ‘non-lipid pleiotropic’ pathways. This study postulated a role of CoQ$_{10}$ as a potential surrogate marker for improvement in endothelial function in resistance vessels, and it was also hypothesised that further benefits may accrue with concomitant CoQ$_{10}$ supplementation.

The CORONA investigators subsequently measured serum CoQ$_{10}$ in a pre-specified subset of 1,191 patients with ischaemic systolic HF and related this to clinical outcomes. Pa-

---

**Figure 4.** The mevalonate pathway. Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins leads to depletion in products of the pathway including cholesterol and coenzyme Q$_{10}$; reproduced with permission from the Australasian Association of Clinical Biochemists.
tients with lower CoQ_{10} concentrations were older and had more advanced HF. Mortality was significantly higher among patients in the lowest compared to the highest CoQ_{10} tertile in a univariate analysis (HR 1.50; 95% CI 1.04–2.6; p = 0.03), but not in a multivariable analysis. CoQ_{10} was not found to be an independent prognostic variable in HF [55], in contrast with the findings of our previous similar study [26].

Given these observations, and the complex interplay of cholesterol, statin therapy and clinical outcomes in HF, future trials incorporating a CoQ_{10} supplementation arm together with statin may be postulated to confer improved clinical outcomes that CORONA did not show [52].

The conflicting findings from these observational studies also gave further impetus to the establishment of a good randomised controlled clinical trial.

**WHAT ABOUT THE ROLE OF COENZYME Q_{10} FOR CARDIAC FUNCTION IN OTHER SETTINGS?**

Supplementation of CoQ_{10} and also selenium in a cohort of community-dwelling elderly people reduced the progression of cardiac wall tension, as measured by the cardiac biomarker NT-proBNP and CV mortality, mainly in participants whose baseline plasma NT-proBNP ranged from the second to the fourth quintiles of the peptide [56]. This could be interpreted as indicating that the therapeutic response may be more pronounced in participants who are in the early stages of development of cardiac dysfunction and could provide a basis to initiate larger randomised trials evaluating the effect of CoQ_{10} and selenium on patients with HF.

**COMMENTARY**

Q-SYMBOIO concluded that CoQ_{10} supplementation improves symptoms and reduces mortality and major adverse CV events in patients with CHF [1]. It is remarkable however that there was a long gestation of the study from the point of inception [27] to full publication [1]. As the authors indicated, CoQ_{10} is a non-patentable substance, with low budget and it was difficult to achieve competitive recruitment against pharmaceutical trials using licensed drugs [1]. This may at least partly explain why the study was not completed according to the original enrollment plan. Medication use is well documented, although it is difficult to be sure that individual patients were on optimal medical therapy and there may be differences in practice between countries. Baseline characteristics, including duration of CHF, were however well matched between the two treatment groups. NT-proBNP concentrations were more than halved in both study groups at 106 weeks compared to baseline, suggesting that the most severely affected patients had died.

CoQ_{10} deficiency has been implicated in several clinical disorders; in some, such as CHF, there is a biologically plausible rationale why supplementation therapy may confer a clinical benefit. The evidence base in support of a therapeutic role for CoQ_{10} in CHF however is still evolving. Although a landmark study, Q-SYMBOIO is still a relatively small trial by pharmaceutical standards. In order to influence clinical behaviour on a more significant scale, it should ideally be replicated independently. It is hoped that its recent publication [1] will stimulate further interest and impetus to undertake such intervention trials.

**Conflict of interest: none declared**

**References**

19. Mohr D, Bowry WV, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within...


